Evidence map›Paper›PMID 34118193›Full record

ArticleMolecular cell2021

Global analysis of protein-RNA interactions in SARS-CoV-2-infected cells reveals key regulators of infection.

Wael Kamel, Marko Noerenberg, Berati Cerikan, Honglin Chen, Aino I Järvelin, Mohamed Kammoun, Jeffrey Y Lee, Ni Shuai, Manuel Garcia-Moreno, Anna Andrejeva and 11 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 1 pooled it
13.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. SFTSV NSs protein is a tick antiviral RNAi response suppressor.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  6. Article
  7. Article
  8. Enzymology of the metazoan tRNA ligase complex: a lifetime in cycles.Cellular and molecular life sciences : CMLS · 2026
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 3 countries.

Wael KamelMRC-University of Glasgow Centre for Virus Research, G61 1QH Glasgow, Scotland, UK; Department of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Marko NoerenbergMRC-University of Glasgow Centre for Virus Research, G61 1QH Glasgow, Scotland, UK; Department of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Berati CerikanDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, 69120 Heidelberg, Germany; German Center for Infection Research, Heidelberg Partner Site, 69120 Heidelberg, Germany.
Honglin ChenDepartment of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Aino I JärvelinDepartment of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Mohamed KammounGerman Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Jeffrey Y LeeDepartment of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Ni ShuaiGerman Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Manuel Garcia-MorenoDepartment of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Anna AndrejevaDepartment of Biochemistry, University of Cambridge, CB2 1GA Cambridge, UK.
Michael J DeeryDepartment of Biochemistry, University of Cambridge, CB2 1GA Cambridge, UK.
Natasha JohnsonMRC-University of Glasgow Centre for Virus Research, G61 1QH Glasgow, Scotland, UK.
Christopher J NeufeldtDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, 69120 Heidelberg, Germany; German Center for Infection Research, Heidelberg Partner Site, 69120 Heidelberg, Germany.
Mirko CorteseDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, 69120 Heidelberg, Germany; German Center for Infection Research, Heidelberg Partner Site, 69120 Heidelberg, Germany.
Michael L KnightSir William Dunn School of Pathology, University of Oxford, South Parks Road, OX1 3RE Oxford, UK.
Kathryn S LilleyDepartment of Biochemistry, University of Cambridge, CB2 1GA Cambridge, UK.
Javier MartinezCenter of Medical Biochemistry, Max Perutz Labs, Medical University of Vienna, Vienna, Austria.
Ilan DavisDepartment of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK.
Ralf BartenschlagerDepartment of Infectious Diseases, Molecular Virology, Heidelberg University, 69120 Heidelberg, Germany; German Center for Infection Research, Heidelberg Partner Site, 69120 Heidelberg, Germany; Division Virus-Associated Carcinogenesis, Germany Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. Electronic address: ralf.bartenschlager@med.uni-heidelberg.de.
Shabaz MohammedDepartment of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK; Department of Chemistry, University of Oxford, Mansfield Road, OX1 3TA Oxford, UK; The Rosalind Franklin Institute, OX11 0FA Oxfordshire, UK. Electronic address: shabaz.mohammed@chem.ox.ac.uk.
Alfredo CastelloMRC-University of Glasgow Centre for Virus Research, G61 1QH Glasgow, Scotland, UK; Department of Biochemistry, University of Oxford, South Parks Road, OX1 3QU Oxford, UK. Electronic address: alfredo.castello@glasgow.ac.uk.
University of Oxford · GBMRC University of Glasgow Centre for Virus Research · GBUniversity of Cambridge · GBGerman Cancer Research Center · DEGerman Center for Infection Research · DEHeidelberg University · DEMedical University of Vienna · AT

Funding

Austrian Science Fund FWF P 29888Medical Research Council MC_PC_19026Medical Research Council MC_UU_12014/10Medical Research Council MC_UU_12014/12Medical Research Council MR/L019434/1Medical Research Council MR/R021562/1Wellcome Trust 110170/Z/15/ZWellcome Trust 209412/Z/17/Z
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 relies on cellular RNA-binding proteins (RBPs) to replicate and spread, although which RBPs control its life cycle remains largely unknown. Here, we employ a multi-omic approach to identify systematically and comprehensively the cellular and viral RBPs that are involved in SARS-CoV-2 infection. We reveal that SARS-CoV-2 infection profoundly remodels the cellular RNA-bound proteome, which includes wide-ranging effects on RNA metabolic pathways, non-canonical RBPs, and antiviral factors. Moreover, we apply a new method to identify the proteins that directly interact with viral RNA, uncovering dozens of cellular RBPs and six viral proteins. Among them are several components of the tRNA ligase complex, which we show regulate SARS-CoV-2 infection. Furthermore, we discover that available drugs targeting host RBPs that interact with SARS-CoV-2 RNA inhibit infection. Collectively, our results uncover a new universe of host-virus interactions with potential for new antiviral therapies against COVID-19.

Indexed as

A549 CellsCOVID-19HumansProteomeRNA-Binding ProteinsRNA, ViralSARS-CoV-2Viral ProteinsVirus ReplicationProteomeRNA-Binding ProteinsRNA, ViralViral ProteinsantiviralsCOVID-19host-virus interactionsHSP90ribonucleoproteinRNARNA-binding proteinRNA interactomeSARS-CoV-2tRNA ligaseviral replication

Identifiers

PMID34118193
PMCPMC8142890
OpenAlexW3165280603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.